1
|
Siciliano M, Tornambè S, Del Corvo M, Granai M, Mundo L, Sapienza M, Arcuri F, Mancini V, Santi R, Di Stefano G, Marafioti T, Ott G, Siebert R, Fend LQ, Fend F, Pileri S, Leoncini L, Lazzi S. EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA. Leuk Res 2022. [DOI: 10.1016/s0145-2126(22)00206-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
2
|
Del Corvo M, Sapienza M, Siciliano M, Tornambè S, Mazzara S, Granai M, Mundo L, Arcuri F, Mancini V, Ferrara D, Ott G, Siebert R, Fend LQ, Fend F, Pileri S, Lazzi S, Leoncini L. “BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION”: NEITHER BURKITT-LYMPHOMA NOR DIFFUSE LARGE B-CELL LYMPHOMA. WHAT THE MICROENVIRONMENT TELLS US. Leuk Res 2022. [DOI: 10.1016/s0145-2126(22)00262-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
3
|
Vogelsberg A, Steinhilber J, Mankel B, Federmann B, Schmidt J, Montes-Mojarro IA, Hüttl K, Rodriguez-Pinilla M, Baskaran P, Nahnsen S, Piris MA, Ott G, Quintanilla-Martinez L, Bonzheim I, Fend F. [Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma]. Pathologe 2021; 42:122-128. [PMID: 34671837 DOI: 10.1007/s00292-021-01011-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 09/20/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND In situ follicular neoplasia (ISFN) is a t(14;18)(q32;q21)+ precursor lesion of follicular lymphoma (FL), which in turn can transform into diffuse large B‑cell lymphoma (DLBCL). For DLBCL that arise de novo, no precursor lesion is known. Given the high frequency of the t(14;18) translocation in de novo DLBCL as well, we investigated whether they can also arise from ISFN without FL as an intermediate step. OBJECTIVES To investigate the clonal evolution of ISFN to DLBCL - transformed from FL and de novo. MATERIALS AND METHODS Identification of ISFN lesions in patients with DLBCL was performed by BCL2 staining of reactive lymphoid tissues. ISFN and DLBCL were subsequently analyzed by fluorescence in situ hybridization, clonality analyses, sequencing of the t(14;18) breakpoint, and targeted next-generation sequencing. RESULTS 10 cases with paired ISFN and DLBCL samples were identified, 6 of which were de novo DLBCL and 4 transformed from FL. 3 DLBCL carried MYC-rearrangements in addition to the t(14;18) and were classified as high-grade B‑cell lymphoma (HGBL). The clonal relationship of ISFN and DLBCL/HGBL was confirmed for all cases. CREBBP, KMT2D, EZH2, TNFRSF14, and BCL2 were the genes most frequently mutated, with the distribution of private and shared mutations pointing to 2 different scenarios of clonal evolution. In most cases, DLBCL/HGBL, ISFN, and, if also present, FL had evolved divergently from a common progenitor, whereas linear evolution was less frequent. CONCLUSION We show for the first time that t(14;18)+ DLBCL/HGBL can arise directly from ISFN without FL as an intermediate step and that during this progression, divergent evolution is common.
Collapse
Affiliation(s)
- A Vogelsberg
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
| | - J Steinhilber
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - B Mankel
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - B Federmann
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - J Schmidt
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - I A Montes-Mojarro
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - K Hüttl
- Abteilung für Klinische Pathologie, Robert-Bosch-Krankenhaus und Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Deutschland
| | | | - P Baskaran
- Zentrum für Quantitative Biologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland
| | - S Nahnsen
- Zentrum für Quantitative Biologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland
| | - M A Piris
- Abteilung für Pathologie, Fundación Jiménez Díaz, Madrid, Spanien
| | - G Ott
- Abteilung für Klinische Pathologie, Robert-Bosch-Krankenhaus und Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Deutschland
| | - L Quintanilla-Martinez
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - I Bonzheim
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - F Fend
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| |
Collapse
|
4
|
Croci GA, Au-Yeung RKH, Reinke S, Staiger AM, Koch K, Oschlies I, Richter J, Poeschel V, Held G, Loeffler M, Trümper L, Rosenwald A, Ott G, Spang R, Altmann B, Ziepert M, Klapper W. SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status. Ann Oncol 2021; 32:1400-1409. [PMID: 34438040 DOI: 10.1016/j.annonc.2021.08.1991] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 08/04/2021] [Accepted: 08/16/2021] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with respect to outcome. Features of the tumor microenvironment (TME) are associated with prognosis when assessed by gene expression profiling. However, it is uncertain whether assessment of the microenvironment can add prognostic information to the most relevant and clinically well-established molecular subgroups when analyzed by immunohistochemistry (IHC). PATIENTS AND METHODS We carried out a histopathologic analysis of biomarkers related to TME in a very large cohort (n = 455) of DLBCL treated in prospective trials and correlated with clinicopathologic and molecular data, including chromosomal rearrangements and gene expression profiles for cell-of-origin and TME. RESULTS The content of PD1+, FoxP3+ and CD8+, as well as vessel density, was not associated with outcome. However, we found a low content of CD68+ macrophages to be associated with inferior progression-free survival (PFS) and overall survival (OS; P = 0.023 and 0.040, respectively) at both univariable and multivariable analyses, adjusted for the factors of the International Prognostic Index (IPI), MYC break and BCL2/MYC and BCL6/MYC double-hit status. The subgroup of PDL1+ macrophages was not associated with survival. Instead, secreted protein acidic and cysteine rich (SPARC)-positive macrophages were identified as the subtype of macrophages most associated with survival. SPARC-positive macrophages and stromal cells directly correlated with favorable PFS and OS (both, P[log rank] <0.001, P[trend] < 0.001). The association of SPARC with prognosis was independent of the factors of the IPI, MYC double-/triple-hit status, Bcl2/c-myc double expression, cell-of-origin subtype and a recently published gene expression signature [lymphoma-associated macrophage interaction signature (LAMIS)]. CONCLUSIONS SPARC expression in the TME detected by a single IHC staining with fair-to-good interobserver reproducibility is a powerful prognostic parameter. Thus SPARC expression is a strong candidate for risk assessment in DLBCL in daily practice.
Collapse
Affiliation(s)
- G A Croci
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
| | - R K H Au-Yeung
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong
| | - S Reinke
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - A M Staiger
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tübingen, Germany
| | - K Koch
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - I Oschlies
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - J Richter
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - V Poeschel
- Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany
| | - G Held
- DSHNHL Studiensekretariat, Universitätsklinikum des Saarlandes, Homburg, Germany
| | - M Loeffler
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - L Trümper
- Department of Hematology and Oncology, Georg-August Universität, Göttingen, Germany
| | - A Rosenwald
- Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken (CCCMF), Würzburg, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tübingen, Germany
| | - R Spang
- Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany
| | - B Altmann
- DSHNHL Studiensekretariat, Universitätsklinikum des Saarlandes, Homburg, Germany
| | - M Ziepert
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - W Klapper
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| |
Collapse
|
5
|
Collinge BJ, Hilton LK, Wong J, Ben‐Neriah S, Rushton CK, Slack GW, Farinha P, Cook JR, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami G, Jaffe ES, Weisenburger DD, Chan WC, Holte H, Beiske K, Fu K, Delabie J, Pittaluga S, Feldman AL, Savage KJ, Mungall AJ, Staudt LM, Steidl C, Rimsza LM, Morin RD, Scott DW. CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH‐GRADE B‐CELL LYMPHOMA, NOS – AN LLMPP PROJECT. Hematol Oncol 2021. [DOI: 10.1002/hon.13_2880] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - L. K Hilton
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - J. Wong
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - S. Ben‐Neriah
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - C. K. Rushton
- Simon Fraser University Molecular Biology and Biochemistry Burnaby Canada
| | - G. W. Slack
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - P. Farinha
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - J. R. Cook
- Cleveland Clinic Department of Molecular Pathology and Laboratory Medicine Cleveland Ohio USA
| | - G. Ott
- Robert‐Bosch‐Krankenhaus and Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology Department of Clinical Pathology Stuttgart Germany
| | - A. Rosenwald
- University of Wuerzburg Institute of Pathology Wuerzburg Germany
| | - E. Campo
- Hospital Clinic of the University of Barcelona Department of Pathology Barcelona Spain
| | - C. Amador
- University of Nebraska Medical Center Department of Pathology and Microbiology Omaha Nebraska USA
| | - T. C. Greiner
- University of Nebraska Medical Center Department of Pathology and Microbiology Omaha Nebraska USA
| | - P. W. Raess
- Oregon Health & Science University Department of Pathology Portland Oregon USA
| | - J. Y. Song
- City of Hope National Medical Center Department of Pathology Duarte California USA
| | - G. Inghirami
- Weill Cornell Medicine Pathology and Laboratory Medicine New York New York USA
| | - E. S. Jaffe
- National Cancer Institute Laboratory of Pathology Bethesda Maryland USA
| | - D. D. Weisenburger
- City of Hope National Medical Center Department of Pathology Duarte California USA
| | - W. C. Chan
- City of Hope National Medical Center Department of Pathology Duarte California USA
| | - H. Holte
- Oslo University Hospital Department of Oncology Oslo Norway
| | - K. Beiske
- Oslo University Hospital Department of Pathology Oslo Norway
| | - K. Fu
- Roswell Park Cancer Institute Department of Pathology & Laboratory Medicine Buffalo New York USA
| | - J. Delabie
- University Health Network and University of Toronto Department of Laboratory Medicine and Pathobiology Toronto Canada
| | - S. Pittaluga
- National Cancer Institute Laboratory of Pathology Bethesda Maryland USA
| | - A. L. Feldman
- Mayo Clinic College of Medicine Laboratory Medicine and Pathology Rochester Minnesota USA
| | - K. J. Savage
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - A. J. Mungall
- BC Cancer Canada’s Michael Smith Genome Sciences Centre Vancouver Canada
| | - L. M. Staudt
- National Cancer Institute Center for Cancer Research Bethesda Maryland USA
| | - C. Steidl
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - L. M. Rimsza
- Mayo Clinic Department of Laboratory Medicine and Pathology Scottsdale Arizona USA
| | - R. D. Morin
- Simon Fraser University Molecular Biology and Biochemistry Burnaby Canada
| | - D. W. Scott
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| |
Collapse
|
6
|
Collinge BJ, Hilton LK, Wong J, Ben‐Neriah S, Alduaij W, Rushton CK, Slack GW, Farinha P, Miyata‐Takata T, Cook JR, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami G, Jaffe ES, Weisenburger DD, Chan WC, Holte H, Beiske K, Fu K, Delabie J, Pittaluga S, Feldman AL, Sehn LH, Savage KJ, Mungall AJ, Staudt LM, Steidl C, Rimsza LM, Morin RD, Scott DW. THE MUTATIONAL LANDSCAPE OF DOUBLE/TRIPLE‐HIT HIGH‐GRADE B‐CELL LYMPHOMA WITH
BCL2
REARRANGEMENT (DH/TH‐
BCL2
) – AN LLMPP PROJECT. Hematol Oncol 2021. [DOI: 10.1002/hon.65_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
7
|
Hilton LK, Collinge B, Ben‐Neriah S, Grande BM, Slack GW, Farinha P, Miyata‐Takata T, Cook JR, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami G, Jaffe ES, Weisenburger DD, Chan WC, Holte H, Beiske K, Fu K, Delabie J, Pittaluga S, Feldman AL, Sehn LH, Savage KJ, Mungall AJ, Staudt LM, Steidl C, Rimsza LM, Morin RD, Scott DW. THE TOPOLOGY OF
MYC
REARRANGEMENTS IN DOUBLE‐HIT LYMPHOMA IS CONSTRAINED BY THE PRECEDING IGH
‐BCL2
REARRANGEMENT – AN LLMPP PROJECT. Hematol Oncol 2021. [DOI: 10.1002/hon.64_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- L. K. Hilton
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - B. Collinge
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - S. Ben‐Neriah
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | | | - G. W. Slack
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - P. Farinha
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - T. Miyata‐Takata
- Niigata University Graduate School of Medical and Dental Sciences Division of Molecular and Cellular Pathology Niigata Japan
| | - J. R. Cook
- Cleveland Clinic Department of Molecular Pathology and Laboratory Medicine Cleveland Ohio USA
| | - G. Ott
- Robert‐Bosch‐Krankenhaus and Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology Department of Clinical Pathology Stuttgart Germany
| | - A. Rosenwald
- University of Wuerzburg, Institute of Pathology Wuerzburg Germany
| | - E. Campo
- Hospital Clinic Department of Pathology Barcelona Spain
| | - C. Amador
- University of Nebraska Medical Center Department of Pathology and Microbiology Omaha Nebraska USA
| | - T. C. Greiner
- University of Nebraska Medical Center Department of Pathology and Microbiology Omaha Nebraska USA
| | - P. W. Raess
- Oregon Health & Science University Department of Pathology Portland Oregon USA
| | - J. Y. Song
- City of Hope National Medical Center Department of Pathology Duarte California USA
| | - G. Inghirami
- Weill Cornell Medicine Pathology and Laboratory Medicine, New York New York USA
| | - E. S. Jaffe
- National Cancer Institute Laboratory of Pathology Bethesda Maryland USA
| | - D. D. Weisenburger
- City of Hope National Medical Center Department of Pathology Duarte California USA
| | - W. C. Chan
- City of Hope National Medical Center Department of Pathology Duarte California USA
| | - H. Holte
- Oslo University Hospital Department of Oncology Oslo Norway
| | - K. Beiske
- Oslo University Hospital Department of Pathology Oslo Norway
| | - K. Fu
- Roswell Park Cancer Institute Department of Pathology & Laboratory Medicine Buffalo New York USA
| | - J. Delabie
- University Health Network and University of Toronto Department of Laboratory Medicine and Pathobiology Toronto Canada
| | - S. Pittaluga
- National Cancer Institute Laboratory of Pathology Bethesda Maryland USA
| | - A. L. Feldman
- Mayo Clinic College of Medicine Laboratory Medicine and Pathology Rochester Minnesota USA
| | - L. H. Sehn
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - K. J. Savage
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - A. J. Mungall
- Canada's Michael Smith Genome Sciences Centre BC Cancer Research Institute Vancouver Canada
| | - L. M. Staudt
- National Cancer Institute Center for Cancer Research Bethesda Maryland USA
| | - C. Steidl
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| | - L. M. Rimsza
- Mayo Clinic Arizona Department of Laboratory Medicine and Pathology Scottsdale Arizona USA
| | - R. D. Morin
- Simon Fraser University Molecular Biology and Biochemistry Burnaby Canada
| | - D. W. Scott
- BC Cancer Centre for Lymphoid Cancer Vancouver Canada
| |
Collapse
|
8
|
Ott G, Klapper W, Feller AC, Hansmann ML, Möller P, Stein H, Rosenwald A, Fend F. [Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]. Pathologe 2019; 40:157-168. [PMID: 30019203 DOI: 10.1007/s00292-018-0456-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
After 8 years, the WHO has now published the updated version of the 4th edition of the classification of hematopoietic and lymphoid tumors. This update provides a conceptual rewrite of existing entities as well as some new provisional entities and categories, particularly among the aggressive B‑cell lymphomas. Important new diagnostic categories include the high-grade B‑cell lymphomas, the large B‑cell lymphoma with IRF4 rearrangement, and the Burkitt-like lymphoma with 11q aberrations. Of particular importance, new concepts concerning the taxonomy and classification of early lymphoid lesions or precursor lesions are included, such as the in situ follicular neoplasia or the in situ mantle cell neoplasia. In addition, the concept of indolent lymphoproliferations, such as breast-implant-associated anaplastic large cell lymphoma and the indolent T‑cell lymphoproliferative disorder of the gastrointestinal tract, has been strengthened. Finally, diagnostic criteria for existing lymphoma entities have been refined.
Collapse
Affiliation(s)
- G Ott
- Abteilung für Klinische Pathologie, Robert-Bosch-Krankenhaus, und Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Auerbachstraße 110/112, 70376, Stuttgart, Deutschland.
| | - W Klapper
- Institut für Pathologie, Sektion Hämatopathologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland
| | - A C Feller
- Hämatopathologie Lübeck, Lübeck, Deutschland
| | - M L Hansmann
- Senckenberg Institut für Pathologie, Universitätsklinikum Frankfurt, Frankfurt, Deutschland
| | - P Möller
- Institut für Pathologie, Universitätsklinikum Ulm, Ulm, Deutschland
| | - H Stein
- Pathodiagnostik Berlin, Berlin, Deutschland
| | - A Rosenwald
- Pathologisches Institut und Comprehensive Cancer Center Mainfranken, Universität Würzburg, Würzburg, Deutschland
| | - F Fend
- Institut für Pathologie und Neuropathologie, Eberhard-Karls-Universität, Tübingen, Deutschland
| |
Collapse
|
9
|
Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glaß B, Hänel M, Trümper L, Held G, Bentz M, Borchmann P, Dreyling M, Viardot A, Metzner B, Kroschinsky F, Staiger A, Ott G, Rosenwald A, Löffler M, Lenz G, Schmitz N. INTENSIVE IMMUNOCHEMOTHERAPY (R-CHOEP) VS HIGH-DOSE IMMUNOCHEMOTHERAPY (R-MegaCHOEP) IN YOUNG PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A 10-YEAR LONG-TERM FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.104_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F. Frontzek
- Department of Hematology; Oncology and Pneumology, University Hospital Münster; Münster Germany
| | - M. Ziepert
- Institute for Informatics; Statistics and Epidemiology, University Leipzig; Leipzig Germany
| | - M. Nickelsen
- Oncology; Oncology Lerchenfeld, Hamburg; Germany
| | - B. Altmann
- Institute for Informatics; Statistics and Epidemiology, University Leipzig; Leipzig Germany
| | - B. Glaß
- Hematology and Stem Cell Transplantation; Helios-Klinikum Berlin-Buch; Berlin Germany
| | - M. Hänel
- Department of Internal Medicine III; Municipal Hospital Chemnitz; Chemnitz Germany
| | - L. Trümper
- Hematology and Oncology; University Göttingen; Göttingen Germany
| | - G. Held
- Departement of Internal Medicine I; Westpfalz-Klinikum GmbH; Kaiserlautern Germany
| | - M. Bentz
- Department of Internal Medicine III; Municipal Hospital Karlsruhe; Karlsruhe Germany
| | - P. Borchmann
- Department of Internal Medicine I; University Hospital Cologne; Cologne Germany
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University of München; München Germany
| | - A. Viardot
- Department of Internal Medicine III; University Hospital Ulm; Ulm Germany
| | - B. Metzner
- Oncology and Hematology; Hospital Oldenburg; Oldenburg Germany
| | - F. Kroschinsky
- Department Internal Medicine I; University Hospital Carl Gustav Carus; Dresden Germany
| | - A.M. Staiger
- Department of Clinical Pathology; Robert-Bosch Hospital; Stuttgart Germany
| | - G. Ott
- Department of Clinical Pathology; Robert-Bosch Hospital; Stuttgart Germany
| | - A. Rosenwald
- Institute of Pathology; University Würzburg; Würzburg Germany
| | - M. Löffler
- Institute for Informatics; Statistics and Epidemiology, University Leipzig; Leipzig Germany
| | - G. Lenz
- Department of Hematology; Oncology and Pneumology, University Hospital Münster; Münster Germany
| | - N. Schmitz
- Department of Hematology; Oncology and Pneumology, University Hospital Münster; Münster Germany
| |
Collapse
|
10
|
Kneer A, Pfeiffer E, Ott G, Sauer G, Schröder-Luettgen E, Gerteis A. Kam es durch die geänderten Leitlinienempfehlungen zwischen 2006 und 2016 zu einer Reduktion der operativen Eingriffe in 2795 invasiven Mammakarzinomfällen bis zum Erreichen der R0-Resektion? Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Kneer
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie, Stuttgart, Deutschland
| | - E Pfeiffer
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie, Stuttgart, Deutschland
| | - G Ott
- Robert-Bosch-Krankenhaus Stuttgart, Pathologie, Stuttgart, Deutschland
| | - G Sauer
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie, Stuttgart, Deutschland
| | | | - A Gerteis
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie, Stuttgart, Deutschland
| |
Collapse
|
11
|
Ritter B, Pfaff L, Sauer G, Ott G, Aulitzky WE, Gerteis A. Neoadjuvante Chemotherapie (NACT) beim frühen Mammakarzinom: retrospektive Analyse von 346 Fällen bezüglich pathologischer Komplettremission (pCR). Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- B Ritter
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie und Geburtshilfe, Stuttgart, Deutschland
| | - L Pfaff
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie und Geburtshilfe, Stuttgart, Deutschland
| | - G Sauer
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie und Geburtshilfe, Stuttgart, Deutschland
| | - G Ott
- Robert-Bosch-Krankenhaus Stuttgart, Pathologie, Stuttgart, Deutschland
| | - WE Aulitzky
- Robert-Bosch-Krankenhaus Stuttgart, Hamatologie und Onkologie, Stuttgart, Deutschland
| | - A Gerteis
- Robert-Bosch-Krankenhaus Stuttgart, Gynäkologie und Geburtshilfe, Stuttgart, Deutschland
| |
Collapse
|
12
|
Klapper W, Fend F, Feller A, Hansmann ML, Möller P, Stein H, Rosenwald A, Ott G. [Aggressive B‑cell lymphomas : Recommendations from the German Panel of Reference Pathologists in the Competence Network on Malignant Lymphomas on diagnostic procedures according to the current WHO classification, update 2017]. Pathologe 2018; 40:152-156. [PMID: 29666909 DOI: 10.1007/s00292-018-0440-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The update of the 4th edition of the WHO classification for hematopoietic neoplasms introduces changes in the field of mature aggressive B‑cell lymphomas that are relevant to diagnostic pathologists. In daily practice, the question arises of which analysis should be performed when diagnosing the most common lymphoma entity, diffuse large B‑cell lymphoma. We discuss the importance of the cell of origin, the analysis of MYC translocations, and the delineation of the new WHO entities of high-grade B‑cell lymphomas.
Collapse
Affiliation(s)
- W Klapper
- Institut für Pathologie, Sektion Hämatopathologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 14, 24105, Kiel, Deutschland.
| | - F Fend
- Institut für Pathologie und Neuropathologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland
| | - A Feller
- Hämatopathologie Lübeck, Lübeck, Deutschland
| | - M L Hansmann
- Dr. Senckenbergisches Institut für Pathologie, Universitätsklinikum Frankfurt, Frankfurt, Deutschland
| | - P Möller
- Institut für Pathologie, Universitätsklinikum Ulm, Ulm, Deutschland
| | - H Stein
- Pathodiagnostik Berlin, Berlin, Deutschland
| | - A Rosenwald
- Pathologisches Institut, Universität Würzburg, Comprehensive Cancer Center Mainfranken, Mainfranken, Deutschland
| | - G Ott
- Abteilung für Klinische Pathologie, Robert-Bosch-Krankenhaus, Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Deutschland
| |
Collapse
|
13
|
Arnal ML, Dold U, Ehlers CT, Gögler E, Hamperl H, Karrer K, Oberhoffer G, Ott G, Pascher W, Proffe A, Schmolling E, Spiessl B, Thurmayr R, Wildner EP, Scheibe O. Zur Klassifizierung der Geschwulstkrankheiten. Der »gesicherte« TNM-Schlüssel (Erweiterungsvorschlag zu den »General Rules« der UICC). Methods Inf Med 2018. [DOI: 10.1055/s-0038-1636256] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Eine Erweiterung des TNM-Schlüssels für menschliche Tumoren um den Sicherungsmodus wird als Diskussionsgrundlage vorgelegt. Die Erweiterung erscheint zweckmäßig, da bei der Erfassung schwer zugänglicher Krebse bisher subjektive wie objektive Untersuchungsbefunde gleichrangig verwendet wurden. Angaben zur Topik, Histologie und das Befundungsdatum ergänzen die Tumorbeschreibung. Der gesicherte TNM-Schlüssel sollte Teil jeder maschinell auswertbaren Krankengeschichte sein.
Collapse
|
14
|
Briele B, Hotze A, Biersack HJ, Kania U, Vogel J, Lange L, Ott G, Overbeck B. 99mTc-Anti-Granulozyten-Antikörper (BW 250/183) zum Nachweis der Appendizitis. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629595] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
ZusammenfassungIn der vorliegenden Studie wurde bei 50 Patienten mit Verdacht auf Appendizitis eine Immunszintigraphie mit 99mTc-markierten Anti-Granulozyten-Antikörpern (AGAk) durchgeführt. Es erfolgten Sequenzaufnahmen in der Perfusionsphase, statische Aufnahmen von Becken und Abdomen in ventraler und dorsaler Projektion 2 Stunden p.i. und eine ECT-Untersuchung. In allen Fällen wurde entweder durch Operation oder durch Langzeitbeobachtung die Diagnose gesichert. Bei 13 Patienten konnte histologisch eine akute Appendizitis gesichert werden. Von diesen Patienten hatten 11 Patienten in der Entzündungsszintigraphie einen eindeutig positiven Befund in Form einer Aktivitätsmehranreicherung an typischer Stelle gezeigt. Zwei Patienten hatten einen negativen Szintigraphiebefund. Bei den restlichen 37 untersuchten Patienten konnte eine akute Appendizitis ausgeschlossen werden. 29 dieser Patienten hatten auch ein negatives Szintigraphieergebnis, bei 3 Patienten war die Szintigraphie positiv. Bei 5 Patienten blieb die szintigraphische Diagnose unklar. Zwei dieser Patienten zeigten eine deutliche Aktivitätsanreicherung im linken Unter- und Mittelbauch. Hier konnte eine akute Divertikulitis und eine akute Peritonitis als Ursache diagnostiziert werden. Bei den restlichen drei Patienten mit unklarem Szintigraphiebefund konnte eine akute Appendizitis ebenfalls ausgeschlossen werden. Die Szintigraphie mit 99mTc-AGAk ist einfach und schnell durchführbar und den bisherigen Methoden mit Zellmarkierungen in der Diagnostik der akuten Appendizitis überlegen. Die Sensitivität für die Diagnostik der akuten Appendizitis betrug in unseren Untersuchungen 85%, die Spezifität 91%. Chronische oder vernarbte, nicht granulozytär infiltrierte Appendizitiden, bei denen jedoch meist auch keine eindeutige Operationsindikation besteht, konnten - ausgenommen zwei Fälle - mit dieser Methode nicht diagnostiziert werden.
Collapse
|
15
|
Zamò A, Pischimarov J, Schlesner M, Rosenstiel P, Bomben R, Horn H, Grieb T, Nedeva T, López C, Haake A, Richter J, Trümper L, Lawerenz C, Klapper W, Möller P, Hummel M, Lenze D, Szczepanowski M, Flossbach L, Schreder M, Gattei V, Ott G, Siebert R, Rosenwald A, Leich E. Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. Leukemia 2017; 32:685-693. [PMID: 28824170 DOI: 10.1038/leu.2017.270] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Accepted: 08/08/2017] [Indexed: 12/25/2022]
Abstract
Depending on disease stage follicular lymphoma (FL) lack the t(14;18) in ~15-~50% of cases. Nevertheless, most of these cases express BCL2. To elucidate mechanisms triggering BCL2 expression and promoting pathogenesis in t(14;18)-negative FL, exonic single-nucleotide variant (SNV) profiles of 28 t(14;18)-positive and 13 t(14;18)-negative FL were analyzed, followed by the integration of copy-number changes, copy-neutral LOH and published gene-expression data as well as the assessment of immunoglobulin N-glycosylation sites. Typical FL mutations also affected t(14;18)-negative FL. Curated gene set/pathway annotation of genes mutated in either t(14;18)-positive or t(14;18)-negative FL revealed a strong enrichment of same or similar gene sets but also a more prominent or exclusive enrichment of immune response and N-glycosylation signatures in t(14;18)-negative FL. Mutated genes showed high BCL2 association in both subgroups. Among the genes mutated in t(14;18)-negative FL 555 were affected by copy-number alterations and/or copy-neutral LOH and 96 were differently expressed between t(14;18)-positive and t(14;18)-negative FL (P<0.01). N-glycosylation sites were detected considerably less frequently in t(14;18)-negative FL. These results suggest a diverse portfolio of genetic alterations that may induce or regulate BCL2 expression or promote pathogenesis of t(14;18)-negative FL as well as a less specific but increased crosstalk with the microenvironment that may compensate for the lack of N-glycosylation.
Collapse
Affiliation(s)
- A Zamò
- Institute of Pathology, University of Würzburg, Würzburg, Würzburg, Germany.,Department of Diagnostic and Public Health, University of Verona, Verona, Italy.,Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - J Pischimarov
- Institute of Pathology, University of Würzburg, Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - M Schlesner
- Theoretical Bioinformatics (B080), Computational Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - P Rosenstiel
- Institute for Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany
| | - R Bomben
- Department of Translational Research, CRO, Aviano, Italy
| | - H Horn
- Dr Margarete Fischer-Bosch-Institute for Clinical Pharmacology, Stuttgart, Germany
| | - T Grieb
- Institute of Pathology, University of Würzburg, Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - T Nedeva
- Institute of Pathology, University of Würzburg, Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - C López
- Institute for Human Genetics, University Hospital Ulm, Ulm, Germany.,Institute for Human Genetics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A Haake
- Institute for Human Genetics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - J Richter
- Institute for Human Genetics, University Hospital Schleswig-Holstein, Kiel, Germany.,Institute of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - L Trümper
- Department of Hematology and Medical Oncology, University Hospital, Göttingen, Germany
| | - C Lawerenz
- Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - W Klapper
- Institute of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - P Möller
- Institute of Pathology, University Hospital Ulm, Ulm, Germany
| | - M Hummel
- Institute of Pathology, Charité-University Hospital Berlin, Germany
| | - D Lenze
- Institute of Pathology, Charité-University Hospital Berlin, Germany
| | - M Szczepanowski
- Institute of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - L Flossbach
- Institute of Pathology, University of Würzburg, Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - M Schreder
- Medizinische Klinik und Poliklinik II, University Hospital Würzburg, Würzburg, Germany
| | - V Gattei
- Department of Translational Research, CRO, Aviano, Italy
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
| | - R Siebert
- Institute for Human Genetics, University Hospital Ulm, Ulm, Germany.,Institute for Human Genetics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - E Leich
- Institute of Pathology, University of Würzburg, Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| |
Collapse
|
16
|
Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol 2017; 28:1540-1546. [PMID: 28398499 PMCID: PMC5815562 DOI: 10.1093/annonc/mdx128] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not demonstrate a difference in outcomes between R-CHOP-14 and R-CHOP-21 in newly diagnosed DLBCL patients aged 19-88 years, but data on elderly patients have not been reported in detail so far. Here, we provide a subgroup analysis of patients ≥60 years treated on the R-CHOP14v21 trial with extended follow-up. PATIENTS AND METHODS Six hundred and four R-CHOP14v21 patients ≥60 years were included in this subgroup analysis, with a median follow-up of 77.7 months. To assess the impact of MYC rearrangements (MYC-R) and double-hit-lymphoma (DHL) on outcome in elderly patients, we performed a joint analysis of cases with available molecular data from the R-CHOP14v21 (N = 217) and RICOVER-60 (N = 204) trials. RESULTS Elderly DLBCL patients received high dose intensities with median total doses of ≥98% for all agents. Toxicities were similar in both arms with the exception of more grade ≥3 neutropenia (P < 0.0001) and fewer grade ≥3 thrombocytopenia (P = 0.05) in R-CHOP-21 versus R-CHOP-14. The elderly patient population had a favorable 5-year overall survival (OS) of 69% (95% CI: 65-73). We did not identify any subgroup of patients that showed differential response to either regimen. In multivariable analysis including individual factors of the IPI, gender, bulk, B2M and albumin levels, only age and B2M were of independent prognostic significance for OS. Molecular analyses demonstrated a significant impact of MYC-R (HR = 1.96; 95% CI: 1.22-3.16; P = 0.01) and DHL (HR = 2.21; 95% CI: 1.18-4.11; P = 0.01) on OS in the combined trial cohorts, independent of other prognostic factors. CONCLUSIONS Our data support equivalence of both R-CHOP application forms in elderly DLBCL patients. Elderly MYC-R and DHL patients have inferior prognosis and should be considered for alternative treatment approaches. TRIAL NUMBERS ISCRTN 16017947 (R-CHOP14v21); NCT00052936 (RICOVER-60).
Collapse
MESH Headings
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived/administration & dosage
- Antibodies, Monoclonal, Murine-Derived/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Biomarkers, Tumor/genetics
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/adverse effects
- Doxorubicin/administration & dosage
- Doxorubicin/adverse effects
- Drug Administration Schedule
- Female
- Gene Rearrangement
- Humans
- Kaplan-Meier Estimate
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Multivariate Analysis
- Patient Selection
- Precision Medicine
- Prednisone/administration & dosage
- Prednisone/adverse effects
- Proto-Oncogene Proteins c-bcl-2/genetics
- Proto-Oncogene Proteins c-bcl-6/genetics
- Proto-Oncogene Proteins c-myc/genetics
- Risk Factors
- Rituximab
- Time Factors
- Treatment Outcome
- United Kingdom
- Vincristine/administration & dosage
- Vincristine/adverse effects
Collapse
Affiliation(s)
- A. Kühnl
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - D. Cunningham
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - N. Counsell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - E. A. Hawkes
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
- Olivia-Newton John Cancer Research & Wellness Centre, Melbourne, Australia
| | - W. Qian
- Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - P. Smith
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - N. Chadwick
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Lawrie
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - P. Mouncey
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Jack
- HMDS, St James’s Institute of Oncology, Leeds
| | | | - K. M. Ardeshna
- Department of Hematology, University College London, London
- Mount Vernon Cancer Centre, Northwood
| | - J. Radford
- Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester
| | - A. McMillan
- Department of Hematology, Nottingham City Hospital, Nottingham
| | | | - D. Turner
- Department of Hematology, Torbay Hospital, Torquay
| | | | - P. W. Johnson
- Cancer Research UK Center, University of Southampton, Southampton, UK
| | - J. Gambell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Rosenwald
- Institute of Pathology, Würzburg University, Würzburg
| | - G. Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart
| | - H. Horn
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart
| | - M. Ziepert
- Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig
| | - M. Pfreundschuh
- Department of Medicine, Saarland University Medical School, Homburg/Saar, Germany
| | - D. Linch
- Department of Hematology, University College London, London
| |
Collapse
|
17
|
Mottok A, Jurinovic V, Farinha P, Rosenwald A, Ott G, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors J, Sehn L, Gascoyne R, Hoster E, Weigert O, Kridel R. FOXP1
EXPRESSION IS INVERSELY CORRELATED WITH EZH2
MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Mottok
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - V. Jurinovic
- Institute for Medical Informatics and Epidemiology; Ludwig Maximilians University; Munich Germany
| | - P. Farinha
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - G. Ott
- Department of Pathology; Robert-Bosch-Hospital; Stuttgart Germany
| | - W. Klapper
- Department of Pathology, Hematopathology Section and Lymph Node Registry; Christian-Albrechts-University Kiel; Kiel Germany
| | - M. Boesl
- Medical Department III; University Hospital of the Ludwig Maximilians University; Munich Germany
| | - W. Hiddemann
- Medical Department III; University Hospital of the Ludwig Maximilians University; Munich Germany
| | - C. Steidl
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - J.M. Connors
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - L.H. Sehn
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - E. Hoster
- Institute for Medical Informatics and Epidemiology; Ludwig Maximilians University; Munich Germany
| | - O. Weigert
- Medical Department III; University Hospital of the Ludwig Maximilians University; Munich Germany
| | - R. Kridel
- Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre - University Health Network; Toronto Canada
| |
Collapse
|
18
|
Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel R, Delabie J, Weisenburger D, Song J, Chan J, Cook J, Fu K, Greiner T, Smeland E, Holte H, Glinsmann-Gibson B, Gascoyne R, Staudt L, Jaffe E, Connors J, Scott D, Steidl C, Rimsza L. MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS - AN LLMPP PROJECT. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Mottok
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - G.W. Wright
- Biometric Research Branch; National Cancer Institute; Rockville USA
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - G. Ott
- Department of Pathology; Robert-Bosch-Krankenhaus; Stuttgart Germany
| | - C. Ramsower
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| | - E. Campo
- Hematopathology Unit; Hospital Clinic Barcelona; Barcelona Spain
| | - R.M. Braziel
- Department of Pathology; Oregon Health & Science University Portland; Portland USA
| | - J. Delabie
- Department of Pathology; University Health Network; Toronto Canada
| | - D.D. Weisenburger
- Department of Pathology, Hematopathology Section and Lymph Node Registry; City of Hope Medical Center; Duarte USA
| | - J.Y. Song
- Department of Pathology, Hematopathology Section and Lymph Node Registry; City of Hope Medical Center; Duarte USA
| | - J.W. Chan
- Department of Pathology, Hematopathology Section and Lymph Node Registry; City of Hope Medical Center; Duarte USA
| | - J.R. Cook
- Department of Laboratory Medicine and Pathology; Cleveland Clinic; Cleveland USA
| | - K. Fu
- Department of Pathology; University of Nebraska Medical Center; Omaha USA
| | - T. Greiner
- Department of Pathology; University of Nebraska Medical Center; Omaha USA
| | - E. Smeland
- Department of Immunology, Institute for Cancer Research; The Norwegian Radium Hospital; Oslo Norway
| | - H. Holte
- Department of Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital; Oslo University Hospital; Oslo Norway
| | - B. Glinsmann-Gibson
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - L.M. Staudt
- Center for Cancer Research, Lymphoid Malignancies Branch; National Cancer Institute; Bethesda USA
| | - E.S. Jaffe
- Hematopathology Section; National Cancer Institute; Bethesda USA
| | - J.M. Connors
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - D. Scott
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - C. Steidl
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - L.M. Rimsza
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| |
Collapse
|
19
|
Schmidt J, Ramis-Záldivar J, Nadeu F, Gonzalez-Farre B, Navarro A, Dojcinov S, Rosenwald A, Ott G, Campo E, Fend F, Egan C, Jaffe E, Salaverria I, Quintanilla-Martinez L. INTEGRATIVE MUTATIONAL ANALYSIS OF PEDIATRIC-TYPE FOLLICULAR LYMPHOMA REVEALS TNFRSF14
AND MAP2K1
AS THE MOST FREQUENTLY MUTATED GENES. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Schmidt
- Institute of Pathology; University Hospital Tübingen; Tübingen Germany
| | - J. Ramis-Záldivar
- Institut d'Investigacions Biomèdiques August Pi iSunyer; Hospital Clínic; Barcelona Spain
| | - F. Nadeu
- Institut d'Investigacions Biomèdiques August Pi iSunyer; Hospital Clínic; Barcelona Spain
| | - B. Gonzalez-Farre
- Institut d'Investigacions Biomèdiques August Pi iSunyer; Hospital Clínic; Barcelona Spain
| | - A. Navarro
- Institut d'Investigacions Biomèdiques August Pi iSunyer; Hospital Clínic; Barcelona Spain
| | - S. Dojcinov
- Department of Pathology, All Wales Lymphoma Panel; University Hospital Wales; Cardiff UK
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - G. Ott
- Department of Clinical Pathology; Robert-Bosch Hospital; Stuttgart Germany
| | - E. Campo
- Institut d'Investigacions Biomèdiques August Pi iSunyer; Hospital Clínic; Barcelona Spain
| | - F. Fend
- Institute of Pathology; University Hospital Tübingen; Tübingen Germany
| | - C. Egan
- Laboratory of Pathology; National Cancer Institute; Bethesda USA
| | - E. Jaffe
- Laboratory of Pathology; National Cancer Institute; Bethesda USA
| | - I. Salaverria
- Institut d'Investigacions Biomèdiques August Pi iSunyer; Hospital Clínic; Barcelona Spain
| | | |
Collapse
|
20
|
Falkenstern-Ge R, Kimmich M, Wohlleber M, Friedel G, Ott G, Kohlhäufl M. Pneumothorax ex vacuo bei Pleuramesotheliom. Pneumologie 2017. [DOI: 10.1055/s-0037-1598464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | - M Kimmich
- Abteilung für Pneumologische Onkologie, Klinik Schillerhöhe
| | | | - G Friedel
- Thoraxchirurgie, Klinik Schillerhöhe
| | | | - M Kohlhäufl
- Zentrum für Pneumologie und Thoraxchirurgie, Klinik Schillerhöhe
| |
Collapse
|
21
|
Falkenstern-Ge R, Kimmich M, Wohlleber M, Bode-Erdmann S, Huettle K, Grabner A, Friedel G, Ott G, Kohlhäufl M. Metachrone multiple Tumore. Pneumologie 2017. [DOI: 10.1055/s-0037-1598452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | - M Kimmich
- Abteilung für Pneumologische Onkologie, Klinik Schillerhöhe
| | | | | | - K Huettle
- Pathologie, Robert Bosch Krankenhaus
| | | | - G Friedel
- Zentrum für Pneumologie und Thoraxchirurgie, Klinik Schillerhöhe
| | - G Ott
- Pathologie, Robert Bosch Krankenhaus
| | - M Kohlhäufl
- Zentrum für Pneumologie und Thoraxchirurgie, Klinik Schillerhöhe
| |
Collapse
|
22
|
Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann M, Bernd W, Stein H, Pöschel V, Dreyling M, Trümper L, Löffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 2016; 27:1323-9. [DOI: 10.1093/annonc/mdw185] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Accepted: 04/22/2016] [Indexed: 11/14/2022] Open
|
23
|
Lewis R, Mangum M, Wang L, Puhlman M, Evenson K, Remick J, Ott G, Abraham J. Impact of Left Atrial Appendage Occlusion on Thromboembolic Complications in Patients Supported by the Heartmate II Left Ventricular Assist Device. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
24
|
Kohlhäufl M, Falkenstern-Ge R, Kimmich M, Wohlleber M, Friedel G, Kalla C, Ott G. Crizotinib-induzierte rasche Tumorremission bei zwei Patientinnen. Pneumologie 2016. [DOI: 10.1055/s-0036-1572241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Falkenstern-Ge R, Kimmich M, Wohlleber M, Friedel G, Bode S, Ott G, Kohlhäufl M. Nivolumab-induzierte rasche Tumorremission. Pneumologie 2016. [DOI: 10.1055/s-0036-1572239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Schroth W, Winter S, Büttner F, Goletz S, Faißt S, Brinkmann F, Saladores P, Heidemann E, Ott G, Gerteis A, Alscher MD, Dippon J, Schwab M, Brauch H, Fritz P. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype. Breast Cancer Res Treat 2015; 155:85-97. [DOI: 10.1007/s10549-015-3651-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 11/26/2015] [Indexed: 01/08/2023]
|
27
|
Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, Staiger AM, Stuhlmann-Laeisz C, Bernd HW, Feller AC, Hummel M, Lenze D, Stein H, Hartmann S, Hansmann ML, Möller P, Hiddemann W, Dreyling M, Ott G, Rosenwald A. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia 2015; 30:854-60. [PMID: 26621338 DOI: 10.1038/leu.2015.330] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 11/05/2015] [Accepted: 11/13/2015] [Indexed: 01/18/2023]
Abstract
Approximately 15% of follicular lymphomas (FLs) lack breaks in the BCL2 locus. The aim of this study was to better define molecular and clinical features of BCL2-breakpoint/t(14;18)-negative FLs. We studied the presence of BCL2, BCL6 and MYC breaks by fluorescence in situ hybridization and the expression of BCL2, MUM1, CD10, P53 and Ki67 in large clinical trial cohorts of 540 advanced-stage FL cases and 116 early-stage disease FL patients treated with chemotherapy regimens and radiation, respectively. A total of 86% and 53% of advanced- and early-stage FLs were BCL2-breakpoint-positive, respectively. BCL2 was expressed in almost all FLs with BCL2 break and also in 86% and 69% of BCL2-breakpoint-negative advanced- and early-stage FLs, respectively. CD10 expression was significantly reduced in BCL2-breakpoint-negative FLs of all stages and MUM1 and Ki67 expression were significantly increased in BCL2-break-negative early-stage FLs. Patient characteristics did not differ between FLs with and without BCL2 breaks and neither did survival times in advanced-stage FLs. These results suggest that the molecular profile differs to some extent between FLs with and without BCL2 breaks and support the notion that FLs with and without BCL2 breaks belong to the same lymphoma entity.
Collapse
Affiliation(s)
- E Leich
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - E Hoster
- Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany
| | - M Wartenberg
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - M Unterhalt
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - R Siebert
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - K Koch
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - W Klapper
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Engelhard
- Department for Radiotherapy, University Hospital Essen, Essen, Germany
| | - B Puppe
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - H Horn
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - A M Staiger
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - C Stuhlmann-Laeisz
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - H W Bernd
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - A C Feller
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - M Hummel
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - D Lenze
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - H Stein
- Pathodiagnostik Berlin, Berlin, Germany
| | - S Hartmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - M L Hansmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - P Möller
- Institute of Pathology, University Hospital Ulm, Ulm, Germany
| | - W Hiddemann
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - M Dreyling
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
| | - A Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | | |
Collapse
|
28
|
Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 2015; 29:1578-86. [PMID: 25708834 DOI: 10.1038/leu.2015.48] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 01/08/2015] [Accepted: 02/13/2015] [Indexed: 12/16/2022]
Abstract
Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the treatment of malignant lymphomas. Pinatuzumab vedotin is an anti-CD22 ADC and polatuzumab vedotin an anti-CD79B ADC that are both linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). In the present study, we analyzed the activity of these agents in different molecular subtypes of diffuse large B-cell lymphoma (DLBCL) both in vitro and in early clinical trials. Both anti-CD22-MMAE and anti-CD79B-MMAE were highly active and induced cell death in the vast majority of activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL cell lines. Similarly, both agents induced cytotoxicity in models with and without mutations in the signaling molecule CD79B. In line with these observations, relapsed and refractory DLBCL patients of both subtypes responded to these agents. Importantly, a strong correlation between CD22 and CD79B expression in vitro and in vivo was not detectable, indicating that patients should not be excluded from anti-CD22-MMAE or anti-CD79B-MMAE treatment because of low target expression. In summary, these studies suggest that pinatuzumab vedotin and polatuzumab vedotin are active agents for the treatment of patients with different subtypes of DLBCL.
Collapse
MESH Headings
- Antibodies, Monoclonal/pharmacology
- Apoptosis/drug effects
- Blotting, Western
- CD79 Antigens/genetics
- CD79 Antigens/immunology
- Cell Cycle/drug effects
- Cell Proliferation/drug effects
- Clinical Trials, Phase I as Topic
- Cohort Studies
- Flow Cytometry
- Follow-Up Studies
- Humans
- Immunoconjugates/pharmacology
- Immunoenzyme Techniques
- Lymphoma, Large B-Cell, Diffuse/classification
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/immunology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Mutation/genetics
- Neoplasm Staging
- Prognosis
- Sialic Acid Binding Ig-like Lectin 2/genetics
- Sialic Acid Binding Ig-like Lectin 2/immunology
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- M Pfeifer
- Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Germany
| | - B Zheng
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - T Erdmann
- 1] Division of Translational Oncology, Department of Medicine A, University Hospital Münster, Münster, Germany [2] Cluster of Excellence EXC 1003, Cells in Motion Münster, Germany
| | - H Koeppen
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - R McCord
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - M Grau
- Department of Physics, Philipps-University, Marburg, Germany
| | - A Staiger
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
| | - A Chai
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - T Sandmann
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - H Madle
- 1] Division of Translational Oncology, Department of Medicine A, University Hospital Münster, Münster, Germany [2] Cluster of Excellence EXC 1003, Cells in Motion Münster, Germany
| | - B Dörken
- Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Germany
| | - Y-W Chu
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - A I Chen
- Department of Hematology-Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
| | - D Lebovic
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA
| | - G A Salles
- Hematology Department, Hospices Civils de Lyon - Université de Lyon, Pierre-Bénite, France
| | - M S Czuczman
- Department of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - M C Palanca-Wessels
- 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Seattle Genetics Inc, Bothell, WA, USA
| | - O W Press
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - R Advani
- Stanford University Medical Center, Stanford University, Stanford, CA, USA
| | - F Morschhauser
- Department of Hematology, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - B D Cheson
- Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington DC, USA
| | - P Lenz
- Department of Physics, Philipps-University, Marburg, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
| | - A G Polson
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - K E Mundt
- Genentech Inc., 1 DNA Way, South San Francisco, CA, USA
| | - G Lenz
- 1] Division of Translational Oncology, Department of Medicine A, University Hospital Münster, Münster, Germany [2] Cluster of Excellence EXC 1003, Cells in Motion Münster, Germany
| |
Collapse
|
29
|
Puhlman M, Wang L, Sullivan R, Evenson K, Remick J, Ott G, Abraham J. A Weekly Dressing Protocol Reduces the Incidence of Driveline Infection. J Heart Lung Transplant 2015. [DOI: 10.1016/j.healun.2015.01.516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
30
|
Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TFE, Bernd HW, Feller AC, Klapper W, Stuhlmann-Laeisz C, Hummel M, Stein H, Lenze D, Hartmann S, Hansmann ML, Möller P, Cogliatti S, Pfreundschuh M, Trümper L, Loeffler M, Glass B, Schmitz N, Ott G, Rosenwald A. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia 2015; 29:1564-70. [DOI: 10.1038/leu.2015.43] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 02/05/2015] [Accepted: 02/06/2015] [Indexed: 02/02/2023]
|
31
|
Momose S, Weißbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, Geissinger E, Staiger AM, Ott G, Rosenwald A. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia 2015; 29:1789-91. [PMID: 25673238 DOI: 10.1038/leu.2015.34] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- S Momose
- 1] Institute of Pathology, University of Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - S Weißbach
- 1] Institute of Pathology, University of Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - J Pischimarov
- 1] Institute of Pathology, University of Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - T Nedeva
- 1] Institute of Pathology, University of Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - E Bach
- Department of Human Genetics, University of Würzburg, Würzburg, Germany
| | - M Rudelius
- 1] Institute of Pathology, University of Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - E Geissinger
- 1] Institute of Pathology, University of Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - A M Staiger
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - A Rosenwald
- 1] Institute of Pathology, University of Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| |
Collapse
|
32
|
Hartmann S, Mauz-Körholz C, Eichenauer D, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller A, Ott G, Möller P, Rosenwald A, Stein H, Hansmann ML, Körholz D, Klapper W. Variant Histological Patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma in Children Treated in Trials of the GPOH-HD. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Merk T, Ott G, Hetzel M, Bode-Erdmann S. Idiopathische alveoläre Hämorrhagie – eine seltene Ursache von Hämoptysen. Pneumologie 2014. [DOI: 10.1055/s-0034-1368010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
34
|
Falkenstern-Ge R, Kimmich M, Grabner A, Horn H, Friedel G, Ott G, Kohlhäufl M. Primäres Pulmonales Synovialsarkom – Ein Fallbericht. Pneumologie 2014. [DOI: 10.1055/s-0034-1367948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
35
|
Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, Vöhringer MC, Horn H, Ott G, Aulitzky WE, van der Kuip H. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma. Cell Death Dis 2014; 5:e1013. [PMID: 24457957 PMCID: PMC4040662 DOI: 10.1038/cddis.2013.552] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2013] [Revised: 12/12/2013] [Accepted: 12/13/2013] [Indexed: 01/08/2023]
Abstract
Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm with transient response to conventional chemotherapy. We here investigated the role of the Bcl-2 homology domain 3-only protein NOXA for life–death decision in MCL. Surprisingly, NOXA (PMAIP1) mRNA and NOXA protein levels were extremely discrepant in MCL cells: NOXA mRNA was found to be highly expressed whereas NOXA protein levels were low. Chronic active B-cell receptor signaling and to a minor degree cyclin D1 overexpression contributed to high NOXA mRNA expression levels in MCL cells. The phoshatidyl-inositol-3 kinase/AKT/mammalian target of rapamycin pathway was identified as the major downstream signaling pathway involved in the maintenance of NOXA gene expression. Interestingly, MCL cells adapt to this constitutive pro-apoptotic signal by extensive ubiquitination and rapid proteasomal degradation of NOXA protein (T½∼15–30 min). In addition to the proteasome inhibitor Bortezomib, we identified the neddylation inhibitor MLN4924 and the fatty acid synthase inhibitor Orlistat as potent inducers of NOXA protein expression leading to apoptosis in MCL. All inhibitors targeted NOXA protein turnover. In contrast to Bortezomib, MLN4924 and Orlistat interfered with the ubiquitination process of NOXA protein thereby offering new strategies to kill Bortezomib-resistant MCL cells. Our data, therefore, highlight a critical role of NOXA in the balance between life and death in MCL. The discrepancy between NOXA transcript and protein levels is essential for sensitivity of MCL to ubiquitin-proteasome system inhibitors and could therefore provide a druggable Achilles' heel of MCL cells.
Collapse
Affiliation(s)
- M A Dengler
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Auerbachstr. 112, Stuttgart 70376, Germany
| | - A Weilbacher
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Auerbachstr. 112, Stuttgart 70376, Germany
| | - M Gutekunst
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Auerbachstr. 112, Stuttgart 70376, Germany
| | - A M Staiger
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Auerbachstr. 112, Stuttgart 70376, Germany
| | - M C Vöhringer
- Second Department of Internal Medicine, Oncology and Hematology, Robert-Bosch-Hospital, Auerbachstr. 110, Stuttgart 70376, Germany
| | - H Horn
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Auerbachstr. 112, Stuttgart 70376, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Hospital, Auerbachstr. 110, Stuttgart 70376, Germany
| | - W E Aulitzky
- Second Department of Internal Medicine, Oncology and Hematology, Robert-Bosch-Hospital, Auerbachstr. 110, Stuttgart 70376, Germany
| | - H van der Kuip
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Auerbachstr. 112, Stuttgart 70376, Germany
| |
Collapse
|
36
|
Fujii T, Suzuki S, Shinozaki M, Tanaka H, Bell S, Cooper S, Lomonte C, Libutti P, Chimienti D, Casucci F, Bruno A, Antonelli M, Lisi P, Cocola L, Basile C, Negri A, Del Valle E, Zanchetta M, Zanchetta J, Di Vico MC, Ferraresi M, Pia A, Aroasio E, Gonella S, Mongilardi E, Clari R, Moro I, Piccoli GB, Gonzalez-Parra E, Rodriguez-Osorio L, Ortiz-Arduan A, de la Piedra C, Egido J, Perez Gomez MV, Tabikh AA, Afsar B, Kirkpantur A, Imanishi Y, Yamagata M, Nagata Y, Ohara M, Michigami T, Yukimura T, Inaba M, Bieber B, Robinson B, Mariani L, Jacobson S, Frimat L, Bommer J, Pisoni R, Tentori F, Ciceri P, Elli F, Brancaccio D, Cozzolino M, Adamczak M, Wiecek A, Kuczera P, Sezer S, Bal Z, Tutal E, Kal O, Yavuz D, Y ld r m I, Sayin B, Ozelsancak R, Ozkurt S, Turk S, Ozdemir N, Lehmann R, Roesel M, Fritz P, Braun N, Ulmer C, Steurer W, Dagmar B, Ott G, Dippon J, Alscher D, Kimmel M, Latus J, Turkvatan A, Balci M, Mandiroglu S, Seloglu B, Alkis M, Serin M, Calik Y, Erkula S, Gorboz H, Afsar B, Mandiroglu F, Kirkpantur A, Lindley E, Cruz Casal M, Rogers S, Pancirova J, Kernc J, Copley JB, Fouque D, Kiss I, Kiss Z, Szabo A, Szegedi J, Balla J, Ladanyi E, Csiky B, orkossy O, Torok M, Turi S, Ambrus C, Deak G, Tisler A, Kulcsar I, K d r V, Altuntas A, Akp nar A, Orhan H, Sezer M, Filiopoulos V, Manolios N, Arvanitis D, Pani I, Panagiotopoulos K, Vlassopoulos D, Rodriguez-Ortiz ME, Canalejo A, Herencia C, Martinez-Moreno JM, Peralta-Ramirez A, Perez-Martinez P, Navarro-Gonzalez JF, Rodriguez M, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Munoz-Castaneda JR, Almaden Y, Munoz-Castaneda JR, Peralta-Ramirez A, Rodriguez-Ortiz M, Herencia C, Martinez-Moreno J, Lopez I, Aguilera-Tejero E, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Rodriguez M, Almaden Y, Hanafusa N, Masakane I, Ito S, Nakai S, Maeda K, Suzuki H, Tsunoda M, Ikee R, Sasaki N, Sato M, Hashimoto N, Wang MH, Hung KY, Chiang CK, Huang JW, Lu KC, Lang CL, Okano K, Yamashita T, Tsuruta Y, Hibi A, Miwa N, Kimata N, Tsuchiya K, Nitta K, Akiba T, Sasaki N, Tsunoda M, Ikee R, Sato M, Hashimoto N, Harb L, Komaba H, Kakuta T, Suzuki H, Suga T, Fukagawa M, Kikuchi H, Shimada H, Karasawa R, Suzuki M, Zhelyazkova-Savova M, Gerova D, Paskalev D, Ikonomov V, Zortcheva R, Galunska B, Jean G, Deleaval P, Hurot JM, Lorriaux C, Mayor B, Chazot C, Vannucchi H, Vannucchi MT, Martins JC, Merino JL, Teruel JL, Fernandez-Lucas M, Villafruela JJ, Bueno B, Gomis A, Paraiso V, Quereda C, Ibrahim FH, Fadhlina NZ, Ng EK, Thong KM, Goh BL, Sulaiman DM, Fatimah DAN, Evi DO, Siti SR, Wilson RJ, Keith M, Copley JB, Gros B, Galan A, Gonzalez-Parra E, Herrero JA, Oyaguez I, Keith M, Casado MA, Lucisano S, Coppolino G, Villari A, Cernaro V, Lupica R, Trimboli D, Aloisi C, Buemi M. CKD-MBD II. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Abstract
Grey zone lymphomas are lymphatic tumors that cannot be assigned to a defined lymphoma entity due to morphological, clinical or genetic reasons. As a defining criterion they present with features of two overlapping entities or features that are intermediate. Such lymphomas may represent a grey zone in the differentiation between indolent and aggressive lymphomas. Often they may show morphological features of one entity but be more related to another entity with respect to the immunophenotype and/or genetic constitution, such as lymphomas in the grey zone between primary mediastinal large B-cell lymphoma and primary nodal diffuse large B-cell lymphoma. The B-cell lymphoma, unclassified, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma has recently been recognized as a provisional category in the updated WHO 2008 classification of malignant lymphomas. This corresponds to a practical lymphoma category that obviously contains several entities with a Burkitt-like appearance and aggressive clinical behavior. Genetically, tumors in this category are frequently characterized by an atypical MYC translocation and complex karyotypic alterations. As yet, no adequate therapy concept exists.
Collapse
Affiliation(s)
- M M Ott
- Pathologisches Institut, Caritas-Krankenhaus, Bad Mergentheim, Deutschland
| | | | | | | |
Collapse
|
38
|
Falkenstern-Ge RF, Wohlleber M, Kimmich M, Bode-Erdmann S, Ott G, Kohlhäufl M. Späte pulmonale Metastasierung vom Endometriumkarzinom 14 und 17 Jahre nach chirurgischer Resektion. Pneumologie 2013. [DOI: 10.1055/s-0033-1334570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Falkenstern-Ge RF, Bode-Erdmann S, Ott G, Wohlleber M, Kohlhäufl M. Pulmonale Metastasierung eines Schweißdrüsenkarzinoms 10 Jahre nach chirurgischer Resektion. Pneumologie 2013. [DOI: 10.1055/s-0033-1334571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Liu J, Liu J, Liu Y, Xu Y, Zhao X, Qian J, Sun B, Xing C, Kanda R, Hamada C, Nakano T, Wakabayashi K, Io H, Horikoshi S, Tomino Y, Ishimatsu N, Miyamoto T, Morimoto H, Nakamata J, Baba R, Kanegae K, Serino R, Kabashima N, Otsuji Y, Doi Y, Tamura M, Nakamata J, Morimoto H, Baba R, Ishimatsu N, Miyamoto T, Kanegae K, Serino R, Kabashima N, Otsuji Y, Doi Y, Tamura M, Kusumoto T, Fukami K, Yamagishi SI, Ueda S, Kaida Y, Hazama T, Nakayama Y, Ando R, Obara N, Okuda S, Tamura M, Matsumoto M, Miyamoto T, Kanegae K, Furuno Y, Serino R, Kabashima N, Otsuji Y, Bang-Gee H, Mazzotta L, Rosati A, Carlini A, Henriques VT, Zangiacomi Martinez E, Divino-Filho JC, Pecoits-Filho R, Cardeal Da Costa JA, Henriques VT, Henriques VT, Gama Axelsson T, Lindholm B, Carrero JJ, Heimburger O, Stenvinkel P, Qureshi AR, Akazawa M, Uno T, Kanda E, Maeda Y, Aktsiali M, Aktsiali M, Antonopoulou S, Tsiolaki K, Bakirtzi N, Patrinou A, Georgopoulou M, Liaveri P, Afentakis N, Tsirpanlis G, Hasegawa T, Nishiwaki H, Hirose M, Komukai D, Tayama H, Koiwa F, Yoshimura A, Lui SL, Lui S, Yung S, Tang C, Ng F, Lo WK, Chan TM, Koo HM, Doh FM, Yoo DE, Oh HJ, Yoo TH, Choi KH, Kang SW, Han DS, Han SH, Fernandes N, Fernandes N, Bastos MG, Gianotti Franco MR, Chaoubah A, Gloria Lima MD, Pecoits-Filho R, Divino-Filho JC, Qureshi AR, Kang S, Do J, Cho K, Park J, Yoon K, Chen JB, Cheng BC, Chen TC, Su YJ, Wu CH, Park Y, Jeon J, Tsikeloudi M, Pateinakis P, Patsatsi K, Manou E, Sotiriadis D, Tsakiris D, Teixeira L, Rodrigues A, Carvalho MJ, Cabrita A, Mendonca D, Kang S, Do J, Park J, Cho K, Yoon K, Bruschi M, Candiano G, Santucci L, Luzio S, Cannavo R, Ghiggeri GM, Verrina E, Varadarajan Y, Raju B, Cho KH, Do J, Kang S, Park JW, Yoon KW, Kim TW, Kimmel M, Braun N, Latus J, Alscher MD, Struijk D, Van Esch S, Krediet RT, Fernandes N, Van den Beukel T, Hoekstra T, Tirapani L, De Andrade Bastos K, Pecoits-Filho R, Qureshi AR, Bastos M, Dekker F, Divino-Filho JC, Yasuhisa T, Kanai H, Harada K, Kawai Y, Sugiyama H, Ito Y, Tsuruya K, Yoshida H, Maruyama H, Goto S, Nakayama M, Nakamoto H, Morinaga H, Matsuo S, Makino H, DI Gioia MC, Gallar P, Laso N, Rodriguez I, Cobo G, Oliet A, Hynostroza J, Herrero JC, Mon C, Ortiz M, Vigil A, Tomo T, Portoles J, Uta S, Uta S, Tato AM, Lopez-Sanchez P, Rivera M, Rodriguez-Pena R, Del Peso G, Ortega M, Felipe C, Tsampikaki E, Aperis G, Kaikis A, Paliouras C, Karvouniaris N, Maragaki M, Alivanis P, Kortus-Gotze B, Hoferhusch T, Hoyer J, Martino F, Kaushik M, Rodighiero MP, Creapldi C, Ronco C, Lacquaniti A, Lacquaniti A, Donato V, Fazio MR, Lucisano S, Cernaro V, Lupica R, Buemi M, Aloisi C, Uno T, Akazawa M, Kanda E, Maeda Y, Bavbek Ruzgaresen N, Secilmis S, Yilmaz H, Akcay A, Duranay M, Akalin N, Akalin N, Altiparmak MR, Trabulus S, Yalin AS, Ataman R, Serdengecti K, Schneider K, Bator B, Niko B, Braun N, Peter F, Ulmer C, Joerg L, Martin K, Dagmar B, German O, Fabian R, Juergen D, Stephan S, Dominik A, Latus J, Latus J, Ulmer C, Fritz P, Rettenmaier B, Hirschburger S, Segerer S, Biegger D, Lang T, Ott G, Kimmel M, Alscher MD, Braun N, Habib M, Korte M, Hagen M, Dor F, Betjes M, Habib M, Hagen M, Korte M, Zietse R, Dor F, Betjes M, Latus J, Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D, Lang T, Ott G, Scharpf C, Kimmel M, Alscher MD, Braun N, Habib M, Korte M, Zietse R, Betjes M, Chang TI, Shin DH, Oh HJ, Kang SW, Han DS, Yoo TH, Han SH, Choi HY, Lee YK, Kim BS, Han SH, Yoo TH, Park HC, Lee HY, Horimoto N, Tuji K, Kitamura S, Sugiyama H, Makino H, Isshiki R, Isshiki R, Iwagami M, Tsutsumi D, Mochida Y, Ishioka K, Oka M, Maesato K, Moriya H, Ohtake T, Hidaka S, Kobayashi S, Higuchi C, Tanihata Y, Ishii M, Sugimoto H, Sato N, Kyono A, Ogawa T, Nishimura H, Otsuka K, Cho KH, Do JY, Kang S, Park JW, Yoon KW, Kim TW, Du Halgouet C, Latifa A, Anne Sophie V, Emmanuel D, Christine R, Francois V, Grzelak T, Czyzewska-Majchrzak L, Kramkowska M, Witmanowski H, Czyzewska K, Janda K, Krzanowski M, Dumnicka P, Sulowicz W, Rroji M, Seferi S, Barbullushi M, Likaj E, Petrela E, Thereska N, Cabiddu G, Dessi E, Arceri A, Laura P, Manca E, Conti M, Cao R, Pani A, Liao CT, Vega Vega O, Mendoza de la Garza A, Correa-Rotter R, Ueda A, Nagai K, Morimoto M, Hirayama A, Owada S, Tonozuka Y, Saito C, Saito C, Yamagata K, Matsuda A, Tayama Y, Ogawa T, Iwanaga M, Noiri C, Hatano M, Kiba T, Kanozawa K, Katou H, Hasegawa H, Mitarai T, Ros-Ruiz S, Ros-Ruiz S, Fuentes-Sanchez L, Jironda-Gallegos C, Gutierrez-Vilches E, Garcia-Frias P, Hernandez-Marrero D, Kang S, Lee S, Cho K, Park J, Yoon K, Do J, Lai X, Chen W, Guo Z, Braide M, Cristina V, Popa SG, Maria M, Eugen M, Martino F, DI Loreto P, DI Loreto P, Ronco C, Rroji M, Seferi S, Barbullushi M, Petrela E, Spahia N, Likaj E, Thereska N, Sanchez Macias LO, Sanchez Macias LO, Lares Castellanos KI, Hernandez Pacheco JA, Vega Vega O, Correa Rotter R, Pedro Ventura A, Olivia S, Teixeira L, Joana V, Francisco F, Maria Joao C, Antonio C, Rodrigues AS, Atas N, Erten Y, Erten Y, Onec K, Inal S, Topal S, Akyel A, Celik B, Okyay GU, Tavil Y, Zeiler M, Monteburini T, Agostinelli RM, Marinelli R, Santarelli S, Erten Y, Erten Y, Inal S, Onec K, Atas N, Okyay GU, Yaylaci C, Sahin G, Tavil Y, Guz G, Sindel S, Pinho A, Cabrita A, Malho Guedes A, Fragoso A, Carreira H, Pinto I, Bernardo I, Leao P, Janda K, Janda K, Krzanowski M, Kusnierz-Cabala B, Dumnicka P, Krasniak A, Chowaniec E, Tabor-Ciepiela B, Sulowicz W, Turkmen K, Ozbek O, Kayrak M, Samur C, Guler I, Tonbul HZ, Rusai K, Herzog R, Kratochwill K, Kuster L, Aufricht C, Meier CM, Fliser D, Schilling MK, Klingele M, Fukasawa M, Fukasawa M, Takeda M, Kamiyama M, Song YR, Kim HJ, Kim SG, Kim JK, Noh JW, Lee YK, Yoon JW, Koo JR. Peritoneal dialysis. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Escher M, Kainikkara TM, Grabner A, Ott G, Stange EF, Herrlinger KR. [Histoplasmosis: uncommon opportunistic infection in a patient with HIV infection]. Dtsch Med Wochenschr 2012; 137:260-4. [PMID: 22294110 DOI: 10.1055/s-0031-1298872] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
HISTORY AND ADMISSION FINDINGS A 19-year-old HIV-positive man was admitted with fever of unknown origin and poor general condition. Antiretroviral therapy had been stopped by the patient eight months prior to admission. INVESTIGATIONS Laboratory tests revealed pancytopenia, high viral load and low count of T-helper cells (13/µl). Computer tomography of the thorax showed small patchy infiltrations. Extensive examinations (microbiology, laboratory tests, multiple investigations) revealed no pathogen. Liver biopsy proved disseminated histoplasmosis. TREATMENT AND COURSE Liposomal amphotericin B was started and switched to oral itraconazole after 14 days with itraconazole. With this treatment the patient condition improved and fever stopped. T-helper cells increased and the patient was discharged. CONCLUSION Disseminated histoplasmosis as an AIDS-defining opportunistic infection is uncommon (particularly as the patient had not been abroad in the last four years) and can be a life-threatening complication. Diagnosis must be confirmed by invasive methods especially in patients with compromised immune status and rapid clinical progression.
Collapse
Affiliation(s)
- M Escher
- Gastroenterologie, Hepatologie und Endokrinologie, Innere Medizin I, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
| | | | | | | | | | | |
Collapse
|
42
|
Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T, De Falco G, Githanga J, Horn H, Nyagol J, Ott G, Palatini J, Pfreundschuh M, Rogena E, Rosenwald A, Siebert R, Croce CM, Stein H. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011; 25:1869-1876. [PMID: 21701491 PMCID: PMC3902789 DOI: 10.1038/leu.2011.156] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2011] [Revised: 04/06/2011] [Accepted: 05/03/2011] [Indexed: 12/19/2022]
Abstract
Sporadic Burkitt lymphoma (sBL) can be delineated from diffuse large B-cell lymphoma (DLBCL) by a very homogeneous mRNA expression signature. However, it remained unclear whether all three BL variants-sBL, endemic BL (eBL) and human immunodeficiency virus-associated BL (HIV-BL)-represent a uniform biological entity despite their differences in geographical occurrence, association with immunodeficiency and/or incidence of Epstein-Barr virus (EBV) infection. To address this issue, we generated micro RNA (miRNA) profiles from 18 eBL, 31 sBL and 15 HIV-BL cases. In addition, we analyzed the miRNA expression of 86 DLBCL to determine whether miRNA profiles recapitulate the molecular differences between BL and DLBCL evidenced by mRNA profiling. A signature of 38 miRNAs containing MYC regulated and nuclear factor-kB pathway-associated miRNAs was obtained that differentiated BL from DLBCL. The miRNA profiles of sBL and eBL displayed only six differentially expressed miRNAs, whereas HIV and EBV infection had no impact on the miRNA profile of BL. In conclusion, miRNA profiling confirms that BL and DLBCL represent distinct lymphoma categories and demonstrates that the three BL variants are representatives of the same biological entity with only marginal miRNA expression differences between eBL and sBL.
Collapse
Affiliation(s)
- D Lenze
- Institute of Pathology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - L Leoncini
- Department of Human Pathology and Oncology, University of Siena, Siena, Italy
| | - M Hummel
- Institute of Pathology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - S Volinia
- Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
| | - CG Liu
- Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
| | - T Amato
- Department of Human Pathology and Oncology, University of Siena, Siena, Italy
| | - G De Falco
- Department of Human Pathology and Oncology, University of Siena, Siena, Italy
| | - J Githanga
- Department of Human Pathology, University of Nairobi, Nairobi, Kenya
| | - H Horn
- Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Würzburg, Stuttgart, Germany
| | - J Nyagol
- Department of Human Pathology, University of Nairobi, Nairobi, Kenya
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Hospital, Stuttgart, Germany
| | - J Palatini
- Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
| | | | - E Rogena
- Department of Human Pathology, University of Nairobi, Nairobi, Kenya
| | - A Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Germany, Campus Kiel, Kiel, Germany
| | - R Siebert
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - CM Croce
- Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
| | - H Stein
- Institute of Pathology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
43
|
Hetzel J, Eberhardt R, Herth FJF, Petermann C, Reichle G, Freitag L, Dobbertin I, Franke KJ, Stanzel F, Beyer T, Möller P, Fritz P, Ott G, Schnabel PA, Kastendieck H, Lang W, Morresi-Hauf AT, Szyrach MN, Muche R, Shah PL, Babiak A, Hetzel M. Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial. Eur Respir J 2011; 39:685-90. [PMID: 21852332 DOI: 10.1183/09031936.00033011] [Citation(s) in RCA: 161] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Forceps, brushes or needles are currently the standard tools used during flexible bronchoscopy when diagnosing endobronchial malignancies. The new biopsy technique of cryobiopsy appears to provide better diagnostic samples. The aim of this study was to evaluate cryobiopsy over conventional endobronchial sampling. A total of 600 patients in eight centres with suspected endobronchial tumours were included in a prospective, randomised, single-blinded multicentre study. Patients were randomised to either sampling using forceps or the cryoprobe. After obtaining biopsy samples, a blinded histological evaluation was performed. According to the definitive clinical diagnosis, the diagnostic yield for malignancy was evaluated by a Chi-squared test. A total of 593 patients were randomised, of whom 563 had a final diagnosis of cancer. 281 patients were randomised to receive endobronchial biopsies using forceps and 282 had biopsies performed using a flexible cryoprobe. A definitive diagnosis was achieved in 85.1% of patients randomised to conventional forceps biopsy and 95.0% of patients who underwent cryobiopsy (p<0.001). Importantly, there was no difference in the incidence of significant bleeding. Endobronchial cryobiopsy is a safe technique with superior diagnostic yield in comparison with conventional forceps biopsy.
Collapse
Affiliation(s)
- J Hetzel
- Dept of Internal Medicine II, University of Tuebingen, Tuebingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Follicular lymphoma (FL) is a germinal centre-derived indolent B-cell lymphoma representing the second most common Non Hodgkin lymphoma in the Western world. This chapter focuses on the pathology of FL and summarizes the current knowledge about genetic and molecular features that are relevant for the pathogenesis of this neoplasm. The translocation t(14;18) is present in approximately 90% of FL leading to the upregulation of the anti-apoptotic protein BCL2, that may constitute a promising molecular target for therapeutic approaches. FL lacking the t(14;18) also exist, and B-cells carrying the t(14;18) can be detected in a subset of healthy individuals. In addition to the t(14;18), secondary genetic alterations are present in most FL and, more recently, deeper insights into the methylation and microRNA expression patterns in the tumour cells have been gained. The tumour microenvironment appears to be particularly important for the biology and the clinical course of FL.
Collapse
Affiliation(s)
- E Leich
- Institute of Pathology, University of Würzburg, Josef-Schneider-Str 2, 97080 Würzburg, Germany.
| | | | | |
Collapse
|
45
|
Jürgen H, Eberhardt R, Herth FJF, Petermann C, Reichle G, Freitag L, Dobbertin I, Franke KJ, Stanzel F, Beyer T, Möller P, Fritz P, Ott G, Schnabel P, Kastendieck H, Lang W, Morresi-Hauf A, Szyrach M, Muche R, Babiak A, Hetzel M. Einfluss der Bronchoskopietechnik auf die Sensitivität von Zangenbiopsie und Kryobiopsie bei endobronchialem Tumorverdacht. Pneumologie 2011. [DOI: 10.1055/s-0031-1272001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
46
|
Falkenstern-Ge RF, Ott G, Friedel G, Markmann H, Kalla J, Kohlhäufl M. Sialadenoma papilliferum of the bronchus: rare tracheobronchial tumor of salivary gland type. Pneumologie 2011. [DOI: 10.1055/s-0031-1272181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Fritz P, Klenk S, Goletz S, Gerteis A, Simon W, Brinkmann F, Heidemann E, Lütttgen E, Ott G, Alscher MD, Schwab M, Dippon J. Clinical impacts of histological subtyping primary breast cancer. Anticancer Res 2010; 30:5137-5144. [PMID: 21187502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND Treatment decisions in breast cancer depend on TNM classification and the assessment of additional variables with have an impact on survival. We examined whether histological subtyping breast cancer as either ductal or lobular is related to disease outcome. PATIENTS AND METHODS We examined a large data base of 14198 breast cancer patients. RESULTS Histological sub-classification of invasive breast cancer as either ductal or lobular is not correlated with disease outcome. However, the data further showed that invasive lobular carcinomas have a higher probability of being oestrogen receptor (ER)- and progesterone receptor (PR)-positive and a lower probability of being c-erbB2-positive. They also showed a higher average age at the time of diagnosis in comparison with invasive ductal carcinoma. Local recurrence rates were lower in invasive lobular carcinoma in comparison with invasive ductal carcinoma (3.5% vs. 6.2%; p = 0.031). The multivariable Cox regression analysis showed that ER, PR, nodal status, grade and tumour size predicted disease outcome with statistical significance, while the histological subtype (invasive ductal or lobular) was not a significant predictor of disease outcome. CONCLUSION Histological sub-classification of invasive breast cancer as either ductal or lobular is not correlated with disease outcome. On the other hand our data gives some indication that lobular and ductal breast cancer appear to be different biological entities.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms/classification
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/metabolism
- Carcinoma, Lobular/pathology
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Multivariate Analysis
- Neoplasm Recurrence, Local/metabolism
- Neoplasm Recurrence, Local/pathology
- Neoplasm Staging
- Receptors, Estrogen/biosynthesis
- Receptors, Progesterone/biosynthesis
Collapse
Affiliation(s)
- P Fritz
- Institute of Digital Medicine, Stuttgart, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Braun N, Kimmel M, Grabner A, Ott G, Alscher M. Claudicatio intermittens, palpable Purpura und Livedo reticularis bei einem 65-jährigen Patienten. Dtsch Med Wochenschr 2010; 135:801-4. [DOI: 10.1055/s-0030-1251933] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Husemann K, Michl M, Ott G, Friedel G, Kohlhäufl M. Nekrotisierende sarkoide Granulomatose als seltene DD pulmonaler Rundherde. Pneumologie 2010. [DOI: 10.1055/s-0030-1251216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Dobbertin I, Friedel G, Jaki R, Michl M, Kimmich M, Hofmann A, Eulenbruch HP, Weber J, Spengler W, Ott G, Kohlhäufl M. Bronchiale Aspergillosen. Pneumologie 2010; 64:171-83. [DOI: 10.1055/s-0029-1215306] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|